Home Site map Contacts
 

Entinostat (MS-275)

Entinostat

Entinostat (MS-275) preferentially inhibits HDAC1 (IC50=300nM) over HDAC3 (IC50=8M) and has no inhibitory activity towards HDAC8 (IC50>100M). MS-275 induces cyclin-dependent kinase inhibitor 1A (p21/CIP1/WAF1), slowing cell growth, differentiation, and tumor development in vivo. Recent studies suggest that MS-275 may be particularly useful as an antineoplastic agent when combined with other drugs, like adriamycin.

Synonyms: SNDX-275; MS-275; MS-27-275; Entinostat; pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate
Technical Data: Molecular Weight - 376.42; Molecular formula - C21H20N4O3; CAS No - 209783-80-2

Ordering Information: Product Number - EC-000.2117; Price and Availability: Inquire This product is also available to buy in bulk quantities.

Related Products: Suberoylanilide Hydroxamic Acid; CI-994 (Tacedinaline); BML-210; M344; MGCD0103 (Mocetinostat); PXD101 (Belinostat); LBH-589 (Panobinostat); Tubastatin A; Scriptaid; NSC 3852; NCH 51; HNHA; BML-281; CBHA; Salermide; Pimelic Diphenylamide; ITF2357 (Givinostat); PCI-24781; APHA Compound 8; Droxinostat; SB939.

References:
1. Saito, A. et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96 4592-4597 (1999).
2. Jaboin, J., et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 62 6108-6115 (2002).
3. Rosato RR, et al. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003; 63: 36373645.


Home  |  About Company  |  Contract Synthesis  |  Cheminformatics Services  |  Info for Chemists  |  Contacts  |  FAQ  |  Site Map

© 2004-2016 Exclusive Chemistry Ltd. All rights reserved.